Allopurinol use in a New Zealand population: prevalence and adherence
- 359 Downloads
Allopurinol is effective for the control of gout and its long-term complications when taken consistently. There is evidence that adherence to allopurinol therapy varies across population groups. This may exacerbate differences in the burden of gout on population groups and needs to be accurately assessed. The aim of this study was to describe the prevalence of allopurinol use in a region of New Zealand using community pharmacy dispensing data and to examine the levels of suboptimal adherence in various population groups. Data from all community pharmacy dispensing databases in a New Zealand region were collected for a year covering 2005/2006 giving a near complete picture of dispensings to area residents. Prevalence of allopurinol use in the region by age, sex, ethnicity and socioeconomic position was calculated. Adherence was assessed using the medication possession ratio (MPR), with a MPR of 0.80 indicative of suboptimal adherence. Multiple logistic regression was used to explore variations in suboptimal adherence across population groups. A total of 953 people received allopurinol in the study year (prevalence 3 %). Prevalence was higher in males (6 %) than in females (1 %) and Māori (5 %) than non-Māori (3 %). The overall MPR during the study was 0.88, with 161 (22 %) of patients using allopurinol having suboptimal adherence. Non-Māori were 54 % less likely to have suboptimal allopurinol adherence compared to Māori (95 % CI 0.30–0.72, p = 0.001). These findings are consistent with those from other studies nationally and internationally and point to the important role for health professionals in improving patient adherence to an effective gout treatment.
KeywordsGout Allopurinol Adherence Pharmacoepidemiology
This work is based on a study funded by the Health Research Council of New Zealand (Grant Number 07/139). The authors would like to thank the pharmacists and people of Gisborne for their advice and the use of their data, as well as the support of Ngati Porou Hauora and Turanga Health. The authors would also like to acknowledge the Local Advisory Committee to the project for their extremely useful insights and comments.
- 20.Horsburgh S, Malik M, Norris P et al (2009) Prescribing and dispensing data sources in New Zealand: their usage and future directions. School of Pharmacy, DunedinGoogle Scholar
- 22.Statistics New Zealand (2009) QuickStats about Gisborne District. Statistics New Zealand, WellingtonGoogle Scholar
- 23.Salmond C, Crampton P, Atkinson J (2007) NZDep2006 index of deprivation. Department of Public Health, University of Otago, WellingtonGoogle Scholar
- 24.Statistics New Zealand (2013) Urban/rural profile (experimental) classification categories. http://www.stats.govt.nz/methods/classifications-and-standards/urban-rural-profile-experimental-class-categories.aspx. Accessed 13 Feb 2013
- 25.WHO Collaborating Centre for Drug Statistics Methodology (2007) Guidelines for ATC classification and DDD assignment. WHO Collaborating Centre for Drug Statistics Methodology, OsloGoogle Scholar
- 26.Apotex NZ Ltd (2011) New Zealand data sheet: Apo-Allopurinol. Apotex NZ Ltd, AucklandGoogle Scholar
- 28.Rothman KJ, Greenland S, Lash TL (2008) Modern epidemiology, 3rd edn. Lippincott Williams & Wilkins, PhiladelphiaGoogle Scholar
- 29.R Core Team (2012) R: a language and environment for statistical computing. R Foundation for Statistical Computing, ViennaGoogle Scholar
- 33.Ministry of Social Development (2010) The social report. Ministry of Social Development, WellingtonGoogle Scholar
- 37.Davis A (2012) Geographical access to medicines in Te Tairawhiti. University of OtagoGoogle Scholar